| Not Yet Recruiting | N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With NCT07261657 | Northwestern University | EARLY_Phase 1 |
| Recruiting | Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors NCT06625190 | University of Florida | Phase 1 / Phase 2 |
| Recruiting | ACTengine® IMA203 Combined With mRNA-4203 NCT06946225 | Immatics US, Inc. | Phase 1 |
| Not Yet Recruiting | EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovar NCT06748872 | Medigene AG | Phase 1 |
| Not Yet Recruiting | Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk T NCT06526897 | ECOG-ACRIN Cancer Research Group | N/A |
| Recruiting | Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor NCT06456359 | University Hospital Heidelberg | Phase 2 |
| Recruiting | Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 NCT06083883 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma NCT06277154 | HRYZ Biotech Co. | Phase 2 |
| Recruiting | Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) NCT06094101 | University Hospital Tuebingen | Phase 1 / Phase 2 |
| Recruiting | SPEARHEAD-3 Pediatric Study NCT05642455 | USWM CT, LLC | Phase 1 / Phase 2 |
| Recruiting | Synovial Sarcoma Registry / Biospecimen Repository NCT05910307 | Children's Hospital of Philadelphia | — |
| Active Not Recruiting | START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer NCT05492682 | Valo Therapeutics Oy | Phase 1 |
| Terminated | A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed C NCT05355753 | C4 Therapeutics, Inc. | Phase 1 |
| Withdrawn | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma NCT05116800 | Brown University | Phase 2 |
| Recruiting | HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced NCT04995003 | Baylor College of Medicine | Phase 1 |
| Withdrawn | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas NCT04906876 | Brown University | Phase 2 |
| Completed | The Registry of Oncology Outcomes Associated With Testing and Treatment NCT04028479 | Taproot Health | — |
| Active Not Recruiting | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma NCT04420975 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Active Not Recruiting | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults NCT04483778 | Seattle Children's Hospital | Phase 1 |
| Completed | Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels NCT04537715 | Epizyme, Inc. | Phase 1 |
| Terminated | CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma NCT04145700 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Completed | Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patie NCT04008238 | Institut Bergonié | N/A |
| Active Not Recruiting | Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma NCT04044768 | USWM CT, LLC | Phase 2 |
| Active Not Recruiting | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults NCT03618381 | Seattle Children's Hospital | Phase 1 |
| Withdrawn | Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin NCT03773510 | Italian Sarcoma Group | Phase 3 |
| Terminated | Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors NCT03604783 | Sumitomo Pharma America, Inc. | Phase 1 |
| Terminated | A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable NCT03520959 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 |
| Terminated | NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) NCT03399448 | University of Pennsylvania | Phase 1 |
| Unknown | Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas NCT03989596 | Maria Sklodowska-Curie National Research Institute of Oncology | Phase 2 |
| Unknown | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies NCT03638206 | Shenzhen BinDeBio Ltd. | Phase 1 / Phase 2 |
| Completed | Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovia NCT03250325 | Takara Bio Inc. | Phase 1 / Phase 2 |
| Recruiting | Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial S NCT03016819 | Advenchen Laboratories, LLC | Phase 3 |
| Active Not Recruiting | MAGE-A4ᶜ¹º³²T for Multi-Tumor NCT03132922 | Adaptimmune | Phase 1 |
| Unknown | Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Ex NCT03651375 | Maria Sklodowska-Curie National Research Institute of Oncology | Phase 2 |
| Terminated | DHEA in Synovial Sarcoma Patients NCT02683148 | Washington University School of Medicine | Phase 1 |
| Active Not Recruiting | Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumo NCT02869217 | University Health Network, Toronto | Phase 1 |
| Completed | A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated NCT02875548 | Epizyme, Inc. | Phase 1 / Phase 2 |
| Completed | Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma NCT02584309 | Washington University School of Medicine | Phase 2 |
| Completed | EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial NCT02601937 | Epizyme, Inc. | Phase 1 |
| Completed | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma NCT02601950 | Epizyme, Inc. | Phase 2 |
| Unknown | Detection of Circulating Tumor Cells in Patients With Sarcomas NCT02983539 | AC Camargo Cancer Center | — |
| Terminated | Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants Wit NCT02609984 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Unknown | T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Mali NCT02457650 | Shenzhen Second People's Hospital | Phase 1 |
| Active Not Recruiting | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients Wi NCT02180867 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Completed | Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases NCT02181829 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma NCT01957709 | Fred Hutchinson Cancer Center | EARLY_Phase 1 |
| Completed | Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy NCT01674101 | St. Jude Children's Research Hospital | N/A |
| Completed | Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma NCT01241162 | University of Louisville | Phase 1 |
| Completed | Sorafenib and Dacarbazine in Soft Tissue Sarcoma NCT00837148 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma NCT00668148 | Eli Lilly and Company | Phase 2 |
| Completed | Bevacizumab and Radiation Therapy for Sarcomas NCT00356031 | Massachusetts General Hospital | Phase 2 |
| Terminated | A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma NCT00140855 | Ludwig Institute for Cancer Research | Phase 2 |
| Completed | Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy NCT00004853 | National Cancer Institute (NCI) | Phase 1 |
| Available | Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel NCT06617572 | USWM CT, LLC | — |
| No Longer Available | Tazemetostat Expanded Access Program for Adults With Solid Tumors NCT03874455 | Epizyme, Inc. | — |